Initial clinical experience of lorcainide (Ro 13-1042), a new antiarrhythmic agent
Lorcainide is a promising antiarrhythmic agent that belongs to the class of local anesthetics. It was tested in 7 patients with malignant ventricular arrhythmias that were resistant to other antiarrhythmic agents. Lorcainide was effective in all cases (complete disappearance of arrhythmias in 6 cases and more than 50% disappearance in the 7th case), and the tolerance was within acceptable limits. The drug was effective at rest, as assessed by 24-h dynamic electrocardiographic monitoring, and during physical exercise. Longer studies with more patients are warranted, since the drug appears to be a promising antiarrhythmic agent.
Key wordsLorcainide antiarrhythmic agent ventricular arrhythmia
Unable to display preview. Download preview PDF.
- 1.Dreifus, L. S., Ogawa, S.: Editorial. Quality of the ideal antiarrhythmic agent. Am. J. Cardiol.39, 466–468 (1977)Google Scholar
- 2.Lown, B., Temte, J. V., Arter, W. J.: Ventricular tachyarrhythmias: clinical aspects. Circulation47, 1364–1381 (1973)Google Scholar
- 3.Lown, B.: New concepts and approaches to sudden cardiac death. Schweiz. Med. Wochenschr.106, 1522–1531 (1976)Google Scholar
- 4.Åstrand, I.: Aerobic work capacity of man and woman with specific reference to age. Acta Physiol. Scand.49 (Supp. 169), 1–92 (1960)Google Scholar
- 5.Lown, B., Wolf, M.: Approaches to sudden death from coronary heart disease. Circulation44, 130–142 (1971)Google Scholar
- 6.Corday, E.: Introduction to the Symposium on identification and management of the candidate for sudden cardiac death. Am. J. Cardiol.39, 813–815 (1977)Google Scholar